IRIA, Corporeal Health Solutions unveil AI-based screening system for covid and TB
The initiative was inaugurated at Kempegowda International Airport, Bengaluru (BLR Airport)
The Indian Radiological & Imaging Association (IRIA), in collaboration with Chennai-based Corporeal Health Solutions (CHS), that specialises in providing innovative, cognitive Artificial Intelligence-based technology to the healthcare industry, has launched state-of-the-art screening systems that streamline COVID-19 and tuberculosis protocols at international airports. Named CHOCO, this innovative product is the first of its kind to be introduced in Asia. The initiative was inaugurated at Kempegowda International Airport, Bengaluru (BLR Airport) by Dr Pushpraj Bhatele.
The enhanced screening solutions combine state-of-the-art AI and chest X-rays and deliver results within nanoseconds. Since the beginning of the pilot study of four weeks conducted by IRIA in collaboration with Bangalore International AirportLtd (BIAL), over 1500 passengers have volunteered and were successfully screened BLR Airport using the new technology.
Speaking on the launch of CHOCO, Dr Mona Bhatia, Coordinator of the AI Committee at IRIA, says, “IRIA is a premier institution in India and is always looking for ways to improve healthcare. During the pandemic, we observed the problems faced in the screenings at the entry and exit ports and saw the need for a solution that was faster and economically viable. Thus, IRIA joined hands with CHS, together with the help of BIAL, to come up with this innovative solution. We believe CHOCO’s enhanced screening solution will inspire ports around the world to implement the same.”
Dr (Major) Vimal Raj, Imaging Diagnostic Adviser at CHS, adds, “CHS is a health-tech company that is changing the way technology is being used for delivering healthcare and diagnosing diseases. We have leveraged our expertise in Artificial Intelligence and Machine Learning to create CHOCHO, thus improving the speed and accuracy of the entire airport screening process, which has become a necessity during the pandemic. Multiple trials across the country have shown exemplary results, and our pilot study has become a valuable case study that proves the viability of the product.”